Pre-made Emactuzumab benchmark antibody ( Whole mAb, anti-CSF1R therapeutic antibody, Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-174
                                      Pre-Made Emactuzumab biosimilar, Whole mAb, Anti-CSF1R Antibody: Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture,  assay development,  animal model development,  PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Emactuzumab (RG-7155) is a humanized monoclonal antibody directed against CSF-1R expressed on macrophages[ and has demonstrated a profound antitumor effect through interference with the CSF-1/CSF-1R axis, along with a manageable safety profile in patients with diffuse-type tenosynovial giant cell tumors (d-TGCT)
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price | 
|---|---|---|---|---|
| GMP-Bios-ab-174-1mg | 1mg | 3090 | Inquiry | Inquiry | 
Size: 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Emactuzumab biosimilar, Whole mAb, Anti-CSF1R Antibody: Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R therapeutic antibody | 
| INN Name | Emactuzumab | 
| Target | CSF1R | 
| Format | Whole mAb | 
| Derivation | Humanized | 
| Species Reactivity | Human | 
| CH1 Isotype | IgG1 | 
| VD LC | Kappa | 
| Highest_Clin_Trial (Jan '20) | Phase-II | 
| Est. Status | Active | 
| 100% SI Structure | 4liq:HL | 
| 99% SI Structure | None | 
| 95-98% SI Structure | None | 
| Year Proposed | 2014 | 
| Year Recommended | 2015 | 
| Companies | Roche;University of Texas M. D. Anderson Cancer Center | 
| Conditions Approved | na | 
| Conditions Active | Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours | 
| Conditions Discontinued | Giant cell tumour of tendon sheath;Pigmented villonodular synovitis | 
| Development Tech | na | 
        
                
                
            
        
        

